Aim of the study is to verify the efficacy and safety of convalescent hyperimmune plasma infusion in hospitalized covid-19 patients non in ITU with pneumonia and respiratory symptoms within seven days from the beginning of symptoms. Efficacy is evaluated by the number of patients who will improve their clinical condition and will not be admitted to ITU. .Safety is considered in relation to adverse reactions to plasma infusion.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
50
immune covid 19 plasma infusion
Ospedale delle Apuane
Massa, Tuscany, Italy
RECRUITINGITU admission
number of patients admitted to ITU after immune plasma transfusion
Time frame: up to 30 days
administration of O2
O2 support will be monitored and reported in its various modes of administration (e.g. nasal cannula, high flow nasal cannula, noninvasive ventilation, mechanical ventilation)
Time frame: up to 30 days
hospital mortality
number of subject deaths
Time frame: up to 90 days
immune plasma infusion adverse reaction
number of participants with treatment-related adverse events as assessed by CTCAE v4.0"
Time frame: in the first 24-48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.